[PDF] Top 20 FOLFIRI plus panitumumab in the treatment of wild type KRAS and wild type NRAS metastatic colorectal cancer

... In this study, even though our patient number was low, we also analysed the tumour localization rates, which have recently become a highly discussed topic. In the retrospective analyses indicating the tumour localization ... See full document

... which panitumumab signi fi cantly improved overall sur- vival (OS ...for KRAS and NRAS exons 2 – 4 ( RAS ...receiving panitumumab+FOLFOX4 vs FOLFOX4 had ≥ 30% tumour shrinkage at week 8, while ... See full document

... the treatment of refractory colorectal cancer. However, KRAS mutation status has been defined as a negative predictive factor for this therapy, a considerable proportion of patients with ... See full document

... characterised KRAS exon 2 wt ...capecitabine plus bevacizumab (CAP-B) or capecitabine (CAP) mainten- ance ...proven metastatic colo- rectal adenocarcinoma; patients with KRAS exon 2 mu- tation ... See full document

... MU KRAS tumors, and balanced between two groups (panitu- mumab and bevacizumab plus FOLFIRI versus FOLFIRI alone), and balanced among (Table ...WT KRAS tumors, the median ages were 59 ... See full document

... in posttreatment biopsies collected at the time of progression identified MET amplifications in three out of seven patients. MET amplifications were then confirmed by FISH (fluores- cence in situ hybridization) analysis ... See full document

... in KRAS wt mCRC patients treated with cetuximab or panitumumab ...resistant, KRAS wild-type tumors [33], a frequency similar to the one documented in the current ...representative ... See full document

... rst-line treatment of RAS WT mCRC in associa- tion with chemotherapy and have recently been compared in different head-to-head randomized ...of panitumumab versus bevacizumab to FOLFOX chemotherapy in the fi ... See full document

... FOLFOXIRI (5-fluorouracil, oxaliplatin and irinotecan) or the doublet FOLFIRI (5-fluorouracil and irinotecan). The trial met its primary endpoint reporting significantly longer progression-free survival (PFS; 12.1 ... See full document

... give FOLFIRI plus C-mab to mCRC patients who have rapid progression and cannot reach third-line ...as KRAS exon 3.4, NRAS, BRAF, and ... See full document

... The use of economic evaluation in health care sector was initially introduced in the 1960’s and has increasingly become an important tool for health care decision makers over time, being applied to both medical ... See full document

... 42 KRAS-wild type colorectal cancer patients, did not show any substantial difference in terms of response rate, progression-free survival and resection rate between anti-epidermal ... See full document

... of panitumumab to chemotherapy significantly improved progression-free survival (PFS) (HR ...on KRAS gene status revealed that the combined therapy significantly improved PFS (HR ...with ... See full document

... both cancer cell proliferation and survival, independently of the EGFR blockade [50, ...anti-EGFR treatment in mCRC [59, 60], their potential application for clinical practice is still ...moAb ... See full document

... of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line treatment for ...receive panitumumab 6 mg/kg every 2 weeks plus ... See full document

... subcutaneous metastatic nod- ules were observed in the right axillary region, right shoulder, right arm and torso; multiple metastatic nodules had developed in the right anterior serratus muscle, right ... See full document

... and NRAS mutations are predictive of resistance to anti-epidermal growth factor receptor (EGFR) ...whenever treatment with an anti-EGFR monoclonal anti- body is ...particular, KRAS gene mutations are ... See full document

... years, panitumumab has remained an important agent in the treatment paradigm for KRAS-WT mCRC with demonstrated efficacy in the first-, second-line and chemorefractory ... See full document

... and NRAS mutation; stage ...pasireotide treatment as per the dosing schedule Figure 1 Individual line plots for biomarkers (A) IGF-1, (B) IGF-2, (C) S100B and (D) ...‘on treatment’ samples for this ... See full document

... Our analysis based on the TAILOR trial is the fi rst study to explore the ef fi cacy and cost of adding cetuximab to fi rst-line FOLFOX-4 in patients with RAS wt mCRC, who are different from the patients with KRAS wt ... See full document